http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Initiative Readies Wholesale Access for the Full Fiber and Cloud Era
-
Arrcus and UfiSpace Collaborate on AI-Optimized Networking Platforms with Enhanced Scale and Security from the Edge to Core
-
Vantiva Unveils New Hawk 5G FWA Home Gateway, designed for 5G SA
-
Palo Alto Networks and Global Partners Announce Secure by Design AI Factories
-
Bitget Lists Fabric Protocol (ROBO) for Spot Trading
-
Bitget Publishes February 2026 Proof of Reserves, Maintaining 169% Total Reserve Ratio
-
Bitget and Obside Partner to Launch Live AI Trading Arena for Copy Trading
-
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Ca
-
Golden Cariboo Resources Intends to Commission Independent NI 43-101 Mineral Resource Estimate for Halo and Main Zones
-
How to Trade Meme Coins in Q1 March: Is APEMARS the Next Meme Coin After Shiba Inu and SPX6900?
-
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
-
New Stamps Feature Quilt Masterpieces From Harriet Powers
-
KEYTRUDA Plus WELIREG Shows 28% Reduction in Cancer Recurrence Risk
-
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlie
-
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carc
-
Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
-
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
-
9 Best Coin Picks Alert: Stage 9 APEMARS Presale Set for Jump for Altcoin Traders
-
Trail Life USA applauds Secretary Hegseth's recognition of its premier boy-focused program
-
BTC yearly returns outperformed by first ever onchain fund memecoin!
-
University Credit Union Earns GreenPath Growth Guru Partner Excellence Award
-
Sanford Heisler Sharp McKnight Secures Compassionate Release for Richard Brown in 1988 Kansas City Fire Case
-
Lexus UPTOWN Honors Hollywood Announces Mario Van Peebles, Taye Diggs, Wood Harris and Omar Benson Miller as its 2026 Honorees
-
Media Statement: National Police Federation Responds to Alberta Budget 2026
-
Novocure to Participate in 2026 Leerink Global Healthcare Conference
-
AMTD Digital reports 565.7% revenue increase for fiscal year 2025
-
AMTD IDEA's Subsidiary AMTD Digital Reports Full Year Results with 565.7% Increase in Revenue, 132.7% Increase in Net Income, and 280.2% Increase in Net Assets
-
Prothena authorizes $100 million share repurchase program
-
Prothena Announces up to $100 Million Share Repurchase Plan
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
-
RECX Appoints TRL Outdoors to Accelerate MAX ATV Dealer Expansion and Commercial Market Growth
-
Thin-Film Electrode Market Outlook 2026-2030: Emerging Trends, Segment Analysis and Investment Scope
-
Photovoltaic Films Market Set for Rapid Growth Analysis: Trends, Demand, Size, and Key Player Forecast 2030
-
DEADLINE ALERT for LAKE and NAVN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
DEADLINE ALERT for KD, PYPL, SMR, and CORT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
Deadline Alert: Kyndryl Holdings, Inc. (KD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
-
Ramaco Resources, Inc. (METC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
-
Deadline Alert: BellRing Brands, Inc. (BRBR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
-
Deadline Alert: NuScale Power Corporation (SMR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
-
Varonis Systems, Inc. (VRNS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
-
Deadline Alert: Smart Digital Group Limited (SDM) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
-
Paysafe Limited (PSFE) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
-
Societe Generale: shares and voting rights as of 23 February 2026
-
Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
-
Battery Backup Unit (BBU) Market to Reach USD 16.6 Billion by 2031 at 11.0% CAGR | Valuates Reports
-
Surgical Simulation Market worth $349.4 million by 2030 | MarketsandMarkets™
-
Metal Fabrication Market size to Hit USD 32.47 Billion by 2032 at 4.7% CAGR, Reports Maximize Market Research
-
Security Testing Market worth $40.99 billion by 2031 | MarketsandMarkets™
-
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients
